|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
modulates neurotransmitter levels
|
|
gptkbp:analysis
|
in progress
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
active
|
|
gptkbp:class
|
phenylpiperazine derivatives
|
|
gptkbp:clinical_trial
|
gptkb:Alchem_Laboratories
gptkb:historical_event
high
ongoing
Phase 2
anxiety disorders
promising
multiple sites
pending publication
|
|
gptkbp:collaborations
|
gptkb:international_partners
Pharmaceutical Research Group
|
|
gptkbp:competitors
|
XYZ-1234
ABC-5678
|
|
gptkbp:developed_by
|
gptkb:Alchem_Laboratories
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:field_of_study
|
in progress
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0730
|
|
gptkbp:ingredients
|
C20 H22 N2 O3
|
|
gptkbp:interacts_with
|
none reported
|
|
gptkbp:invention
|
patented
|
|
gptkbp:investment
|
high
neurology
|
|
gptkbp:is_expected_to
|
moderate to high
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_used_for
|
treatment of neurological disorders
|
|
gptkbp:launch_date
|
2025
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:population
|
patients with chronic conditions
|
|
gptkbp:project
|
late-stage development
|
|
gptkbp:receives_funding_from
|
private investors
government grant
|
|
gptkbp:recruitment
|
ongoing
|
|
gptkbp:regulatory_compliance
|
pending
investigational new drug
|
|
gptkbp:research_areas
|
mental health
psychiatry
University of Medicine
|
|
gptkbp:research_focus
|
neuropharmacology
|
|
gptkbp:safety_features
|
ongoing
under evaluation
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:target_audience
|
adults
elderly
|
|
gptkbp:targets
|
serotonin receptors
|
|
gptkbp:weight
|
338.4 g/mol
|
|
gptkbp:wildlife
|
completed
|
|
gptkbp:year_created
|
gptkb:2020
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|